Clinical Trial Results: Myasthenia Gravis generalised

Product Name: CellCept [mycophenolate mofetil]
Date of Report: 5/28/2007
Phase: III
A prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter, 36-week trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve symptom control with reduced corticosteroids in subjects with myasthenia gravis.

Product Name: CellCept [mycophenolate mofetil]
Date of Report: 9/10/2007
Phase: III
An optional continuation of double-blind treatment for patients who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 (a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 36-week trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve symptom control with reduced corticosteroids in patients with myasthenia gravis).